APOE and Cognitive impairment: Age-dependent genetic effects have been previously described for APOE-ε4 with regard to AD48,51 and progression to mild cognitive impairment and AD52, showing increasing effects until an age of 70–75 years, with reduced effect on later ages48,51,52.